Publisher
Springer International Publishing
Reference56 articles.
1. NooneAM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA,editors. SEER cancer statistics review, 1975–2015. Bethesda: National Cancer Institute; 2018.
https://seer.cancer.gov/csr/1975_2015/
, based on November 2017 SEER data submission, posted to the SEER website, April 2018. Accessed 2 May 2018.
2. Hammel P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.
3. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
4. Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.
5. Varadhachary GR, et al. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol. 2005;8(5):377–84.